Novel therapies for septic shock over the past 4 decades

JAMA

Volumn 306, Issue 2, 2011, Pages 194-199

  Suffredini, Anthony F ^a   Munford, Robert S ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; BRADYKININ; ENDOTOXIN ANTIBODY; GLUCOCORTICOID; HYPERTENSIVE FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BLEEDING; CAUSE OF DEATH; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG FATALITY; DRUG RESEARCH; DRUG TARGETING; FLUID RESUSCITATION; GRAM NEGATIVE BACTERIUM; HUMAN; HYPOTENSION; INFLAMMATION; INTENSIVE CARE UNIT; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE;

EID: 79960156486     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.909     Document Type: Article

References (50)

1. Marshall JC. Sepsis: rethinking the approach to clinical research. J Leukoc Biol. 2008;83(3):471-482. (Pubitemid 351966853)
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554.
3. Centers for Disease Control and Prevention. Quick-Stats: hospitalization rates for patients aged ≥65 years with septicemia or sepsis, by age group - National Hospital Discharge Survey, United States, 2000-2007. MMWR Morb Mortal Wkly Rep. 2010;59(34):1108.
4. Wier LM, Henke R, Friedman B; Agency for Healthcare Research and Quality. Diagnostic groups with rapidly increasing costs by payer, 2001-2007:HCUP statistical brief 91, June 2010. http://www.hcup-us.ahrq.gov/reports/statbriefs/ sb91.pdf. Accessed June 7, 2011.
5. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med. 2003;31(9):2332-2338.
6. ARISE; ANZICS Adult Patient Database Management Committee. The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc. 2007;9(1):8-18.
7. Blanco J, Muriel-Bombín A, Sagredo V, et al; Grupo de Estudios y Análisis en Cuidados Intensivos. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12(6):R158.
8. Munford RS, Suffredini AF. Sepsis, severe sepsis, and septic shock. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia, PA: Churchill Livingstone; 2010:987-1009.
9. Barnett JA, Sanford JP. Bacterial shock. JAMA. 1969;209(10):1514-1517.
10. Weil MH, Spink WW. The schock syndrome associated with bacteremia due to gram-negative bacilli. AMA Arch Intern Med. 1958;101(2):184-193.
11. Hollenberg SM. Vasoactive drugs in circulatory shock. Am J Respir Crit Care Med. 2011;183(7):847-855.
12. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982;307(20):1225-1230. (Pubitemid 12001356)
13. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial: the HA-1A Sepsis Study Group. N Engl J Med. 1991;324(7):429-436.
14. Greenman RL, Schein RM, Martin MA, et al; XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 1991;266(8):1097-1102.
15. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial: rBPI21 Meningococcal Sepsis Study Group. Lancet. 2000;356(9234):961-967.
16. Turgeon AF, Hutton B, Fergusson DA, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146(3):193-203. (Pubitemid 351650633)
17. Bone RC, Balk RA, Cerra FB, et al; ACCP/SCCM Consensus Conference Committee; American College of Chest Physicians/Society of Critical Care Medicine. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644-1655.
18. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect. 2009;15(4):308-318.
19. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166(9):1197-1205. (Pubitemid 35222596)
20. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
21. Marik PE, Pastores SM, Annane D, et al; American College of Critical Care Medicine. Recommendations for the diagnosis and management of cortico-steroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med. 2008;36(6):1937-1949.
22. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238-247.
23. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
24. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002;347(13):1027-1030.
25. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-1341.
26. Nadel S, Goldstein B, Williams MD, et al; Researching severe sepsis and organ dysfunction in children: a global perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007;369(9564):836-843.
27. Eli Lilly and Company. ClinicalTrials.gov Web site. Efficacy and safety of drotrecogin alfa (activated) in adult patients with septic shock: ClinicalTrials.gov identifier: NCT00604214. http://clinicaltrials.gov/ct2/show/ study/NCT00604214?view=results. Accessed May 22, 2011.
28. University of Versailles. ClinicalTrials.gov Web site. Activated protein C and corticosteroids for human septic shock (APROCCHS): ClinicalTrials.gov identifier: NCT00625209. http://clinicaltrials.gov/ct2/show/NCT00625209?term= NCT00625209&rank=1. Accessed May 22, 2011.
29. Sweeney DA, Natanson C, Eichacker PQ. Recombinant human activated protein C, package labeling, and hemorrhage risks. Crit Care Med. 2009;37(1):327-329.
30. Eichacker PQ, Natanson C. Increasing evidence that the risks of rhAPC may outweigh its benefits. Intensive Care Med. 2007;33(3):396-399. (Pubitemid 46333860)
31. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis - practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med. 2006;355(16):1640-1642. (Pubitemid 44583953)
32. Kavanagh BP. The GRADE system for rating clinical guidelines. PLoS Med. 2009;6(9):e1000094.
33. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38(2):367-374.
34. Finfer S. The Surviving Sepsis Campaign: robust evaluation and high-quality primary research is still needed. Crit Care Med. 2010;38(2):683-684.
35. Barochia AV, Cui X, Vitberg D, et al. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2010;38(2):668-678.
36. National Institute of General Medical Sciences. ClinicalTrials.gov Web site. Protocolized care for early septic shock (ProCESS): ClinicalTrials.gov identifier: NCT00510835. http://clinicaltrials.gov/ct2/show/NCT00510835?term= NCT00510835&rank=1. Accessed May 22, 2011.
37. Monash University. ClinicalTrials.gov Web site. Australasian resuscitation in sepsis evaluation randomised controlled trial (ARISE): ClinicalTrials.gov identifier: NCT00975793. http://clinicaltrials.gov/ct2/show/ NCT00975793?term=NCT00975793&rank=1. Accessed May 22, 2011.
38. Rowan K; Intensive Care National Audit and Research Centre. National Institute for Health Researcy Health Technology Assessment Programme Web site. Protocolised management in sepsis (ProMISe): a multicentre, randomised controlled trial of the clinical and cost-effectiveness of early protocolised resuscitation for emerging septic shock: reference 07/37/47. http://www.hta.ac.uk/1860. Accessed May 22, 2011.
39. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-1596. (Pubitemid 43810035)
40. Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Once is not enough: clinical trials in sepsis. Intensive Care Med. 2008;34(11):1955-1960.
41. Munford RS. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol. 2006;1:467-496.
42. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med. 2001;163(2):316-321. (Pubitemid 32158505)
43. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15(5):496-497.
44. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet. 2004;364(9433):545-548. (Pubitemid 39070417)
45. Kushner I. Semantics, inflammation, cytokines and common sense. Cytokine Growth Factor Rev. 1998;9(3-4):191-196. (Pubitemid 29019704)
46. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405(6785):458-462. (Pubitemid 30367422)
47. Perl TM, Dvorak L, Hwang T, Wenzel RP. Longterm survival and function after suspected gram-negative sepsis. JAMA. 1995;274(4):338-345.
48. Quartin AA, Schein RM, Kett DH, Peduzzi PN; Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. Magnitude and duration of the effect of sepsis on survival. JAMA. 1997;277(13):1058-1063.
49. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787-1794.
50. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15-21. (Pubitemid 43032375)